Join the Rheumatoid Arthritis group to help and get support from people like you.
Rheumatoid Arthritis News (Page 3)
Related terms: Arthritis, Arthritis, Rheumatoid, RA, Rheumatoid, Inflamed Joints
Prevalence of Neuropsychiatric Symptoms Up for Autoimmune Rheumatic Disease
TUESDAY, Aug. 1, 2023 – The prevalence of all self-reported neuropsychiatric symptoms is significantly higher in those with systemic autoimmune rheumatic diseases (SARDs) versus controls, according...
Scores Developed for Risk Stratification in Inflammatory Arthritis
TUESDAY, Aug. 1, 2023 – A simple and a comprehensive score have been developed for persons at risk for inflammatory arthritis, according to a study published online Aug. 1 in the Annals of Internal...
Prevalence of Arthritis 305 Per 100,000 Children, Teens in U.S.
THURSDAY, July 20, 2023 – The prevalence of arthritis is 305 per 100,000 children and adolescents in the United States, with higher prevalence among non-Hispanic Black or African American versus...
Got Arthritis Pain? What State You Live In May Matter
WEDNESDAY, July 12, 2023 – If you live in West Virginia you’re more likely to experience joint pain due to arthritis, according to a new study that looked at the differences in pain across states. “...
Treatment Effect of Tofacitinib, Adalimumab Compared in RA
WEDNESDAY, July 12, 2023 – For adults with rheumatoid arthritis (RA), there is a modest reduction in the mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at three months...
FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira
JERSEY CITY, N.J.--(BUSINESS WIRE) May 24, 2023 --Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration ...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan (rituximab), for Adults with Moderate to Severe Rheumatoid Arthritis
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
FDA Approves Yusimry (adalimumab-aqvh), a Biosimilar to Humira
REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) appro...
FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Admini...
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved...
FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis
NASHVILLE, Tenn., Dec. 2, 2019 /PRNewswire/ – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis
NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel
INCHEON, Korea – As of April 2019 – Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved Eticovo (etanercept-ykro), a biosimilar referencing Enbrel (et...
FDA Medwatch Alert: Safety Communication: Xeljanz, Xeljanz XR (tofacitinib) Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients
ISSUE: FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR) was...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
prednisone, ibuprofen, naproxen, meloxicam, aspirin, doxycycline, Norco, diclofenac, methylprednisolone, view more... methotrexate, Vicodin, Humira, Celebrex, Aleve, Advil, Voltaren, triamcinolone, hydroxychloroquine, Plaquenil, cortisone, Motrin, Medrol, Enbrel, indomethacin, Remicade, Lortab, Mobic, Xeljanz, Rituxan, acetaminophen / hydrocodone, Arthritis Pain, adalimumab, Actemra, etanercept, dexamethasone, glucosamine, rituximab, nabumetone, tetracycline, garlic